NMN and NR are the two leading NAD+ precursors; both raise NAD+ in human trials, and the 'which is better' debate splits along the Sinclair (NMN) vs Brenner (NR) camps — with dosing and cost often deciding it.
Two molecules dominate the NAD+ longevity conversation: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are precursors that your cells convert into NAD+ — the coenzyme that powers over 500 enzymatic reactions, drives DNA repair, and regulates the sirtuins your cells rely on for stress resilience. Both have credible researchers, legitimate human data, and real biochemical rationale behind them.
But they are not interchangeable. They enter different metabolic pathways, reach different tissues at different rates, and have meaningfully different bodies of clinical evidence. This guide breaks down everything you need to know to make an evidence-based choice in 2026.
NAD+ does not passively fade — it is actively consumed. As you age, three forces converge to drain your cellular NAD+ pool:
1. CD38 activation. CD38 is an enzyme that degrades NAD+ as part of immune and inflammatory signaling. It increases with age and with chronic low-grade inflammation ("inflammaging"), and it is ruthlessly efficient — a single CD38 molecule can destroy thousands of NAD+ molecules per second.
2. PARP hyperactivation. PARP enzymes repair DNA strand breaks using NAD+ as a substrate. As DNA damage accumulates with age and oxidative stress, PARPs run continuously, consuming large quantities of NAD+.
3. Reduced precursor recycling. The salvage pathway — which recycles nicotinamide back into NAD+ via NAMPT — becomes less efficient with age. NAMPT expression declines, meaning even if you have plenty of the building blocks, your cells are slower at reassembling them.
The result: by your 50s, whole-blood NAD+ concentrations are typically half what they were at age 20–25 (Yoshino et al., Cell Metabolism, 2021). By your 60s and 70s, muscle and liver tissue can show declines of 60–70%. Restoring NAD+ with precursors is the most direct pharmacological lever we currently have to address this.
Both NMN and NR ultimately produce NAD+, but they take different roads to get there — and the road matters for which tissues get the most benefit.
When you take NR orally, it is absorbed in the gut and enters cells via nucleoside transporters. Once inside, two enzymes — NRK1 and NRK2 (nicotinamide riboside kinases) — phosphorylate NR by adding a phosphate group, converting it directly into NMN. NMN is then converted to NAD+ by NMNAT enzymes. So NR requires two enzymatic steps to become NAD+.
There is a complication: a significant fraction of oral NR is hydrolyzed in the gut to plain nicotinamide (NAM) before it ever reaches the bloodstream. NAM can still eventually be converted to NAD+ via the salvage pathway, but it takes longer and passes through more steps. This explains why NR's measured contribution to blood NAD+ uplift, while real, is often described as moderate.
NMN is larger than NR (334 Da vs. 255 Da). For years, researchers assumed it could not cross the plasma membrane directly and had to be first dephosphorylated to NR outside the cell. That view changed substantially with the discovery of a dedicated NMN transporter — Slc12a8 — identified by Yoshino's group at Washington University in 2019. This transporter appears especially active in the small intestine and possibly in muscle tissue, enabling direct NMN uptake without prior conversion to NR.
Once inside the cell, NMN requires only one enzymatic step — via NMNAT — to become NAD+. This mechanistic proximity to NAD+ is the basis for claims that NMN may work faster and be more effective in tissues where Slc12a8 is expressed.
Key point: NR → NMN → NAD+ (two steps). NMN → NAD+ (one step, assuming direct cellular uptake via Slc12a8). Whether this one-step advantage translates into meaningfully higher NAD+ in humans remains an active research question.
| Factor | NMN | NR |
|---|---|---|
| Molecular weight | 334.2 Da | 255.3 Da (as chloride salt: 290.7 Da) |
| Pathway to NAD+ | Direct: NMN → NAD+ (via NMNAT1/2/3) | Two steps: NR → NMN (via NRK1/2) → NAD+ (via NMNAT) |
| Dedicated transporter | Yes — Slc12a8 (gut, muscle; Yoshino lab, 2019) | Enters via nucleoside transporters; no dedicated channel |
| Oral bioavailability | Good; raises blood NAD+ dose-dependently (Irie 2020, Yi 2023) | Moderate; partial gut hydrolysis to NAM lowers efficiency |
| Human trial data | Growing rapidly — Yoshino 2021, Liao 2021, Yi 2023, several ongoing | More established — Martens 2020, Dollerup 2018, Elhassan 2019 |
| Key human finding | Improved muscle insulin sensitivity in postmenopausal women (Yoshino 2021) | Improved muscle NAD+ and mitochondrial function (Martens 2020) |
| Cost per gram | ~$1.20–2.50/g (powder); higher for capsules | ~$1.00–2.00/g (Tru Niagen class); similar range |
| Notable researchers | David Sinclair (Harvard), Shin-ichiro Imai (Wash U) | Charles Brenner (UC Irvine), Johan Auwerx (EPFL) |
| Stability | Degrades in heat/humidity; keep refrigerated | More stable at room temperature |
| Sublingual option | Yes — may bypass gut hydrolysis | Not widely available in sublingual form |
The NMN/NR debate has real scientific personalities behind it, and understanding their positions helps you interpret the literature with appropriate skepticism.
Sinclair, a professor at Harvard Medical School and author of Lifespan, has been the most prominent public champion of NMN. He has stated in interviews and on his podcast that he takes 1,000mg of NMN daily, often combined with resveratrol and metformin. His lab's foundational work on sirtuins — the NAD+-dependent deacylases that regulate aging pathways — established much of the theoretical rationale for why raising NAD+ matters.
Sinclair's group published influential mouse studies showing NMN reverses vascular aging and improves mitochondrial function in skeletal muscle. Critically, he co-authored the 2019 paper identifying Slc12a8 as a direct NMN transporter, which underpins the mechanistic advantage argument for NMN over NR. His financial disclosures include involvement with companies in the longevity supplement space, which critics cite as a reason to weight his advocacy carefully.
Brenner, Chief Scientific Advisor at ChromaDex (which manufactures Tru Niagen, the dominant NR brand), actually discovered NR as a vitamin B3 precursor in 2004 and identified NRK1/2 as the pathway for its conversion. He has been an outspoken critic of what he considers premature or overclaimed NMN advocacy, and has published extensively on NR's safety and efficacy in humans.
Brenner's skepticism of NMN centers on several points: the Slc12a8 transporter data has been partially disputed by other groups who failed to replicate direct NMN cellular uptake; NMN's larger molecular weight genuinely does create absorption challenges; and NMN has fewer large, well-controlled human RCTs. He argues NR's longer human clinical track record makes it the more defensible choice for consumers.
Both researchers have legitimate scientific credentials and legitimate conflicts of interest. The prudent reader treats their public statements as strong priors — not settled verdicts.
A randomized, double-blind, placebo-controlled trial enrolled 25 postmenopausal women with prediabetes. Participants received 250mg/day of NMN or placebo for 10 weeks. The NMN group showed significantly improved skeletal muscle insulin sensitivity and increased expression of genes involved in muscle remodeling and energy metabolism. Whole-blood NAD+ metabolomics confirmed NMN successfully raised NAD+ and downstream metabolites. This is the most rigorous NMN human trial to date, though the sample size is small and the population specific.
A Japanese single-dose safety study in 10 healthy men found 100mg, 250mg, and 500mg single doses of NMN were all well-tolerated with no serious adverse events. NMN raised blood NAD+ and its metabolites (NAAD, MeNAM) dose-dependently. This established the basic safety and pharmacokinetics profile for oral NMN in humans.
A crossover RCT in 30 healthy middle-aged and older adults tested NR 1,000mg/day for 21 days against placebo. NR significantly increased NAD+ and related metabolites in whole blood. Skeletal muscle biopsies showed increased muscle NAD+ and transcriptomic changes consistent with enhanced mitochondrial biogenesis. Blood pressure trended downward in a subgroup with elevated baseline BP. No safety concerns were identified. This remains one of the best-designed NR human studies.
A 12-week RCT in 40 obese men tested NR 1,000mg/day vs. placebo. NR safely and robustly raised NAD+ metabolites. However, this study did not find significant improvements in insulin sensitivity, body composition, or blood pressure — a reminder that raising NAD+ biochemically does not automatically translate into every metabolic outcome. The study remains important for safety data and for calibrating expectations.
The honest summary: NR has more completed human RCTs with more participants across more populations. NMN's human evidence is newer but includes functionally meaningful endpoints (insulin sensitivity in muscle). Neither molecule has a large Phase III-equivalent trial demonstrating hard longevity endpoints in humans — that research will take decades.
Sublingual (under-the-tongue) NMN has become a marketing category, with brands claiming it bypasses gut degradation and delivers NMN directly into the bloodstream via the sublingual mucosa. The theory is sound in principle: oral NMN may face partial hydrolysis by intestinal enzymes before absorption, and sublingual delivery could bypass this.
In practice, the evidence is thin. There are no published head-to-head pharmacokinetic studies in humans comparing sublingual vs. standard oral NMN. One small study found sublingual NMN reached peak blood NMN concentrations faster than capsules, but total NAD+ uplift was not meaningfully different at 24 hours.
The more rigorous Yoshino 2021 trial used standard oral NMN capsules and still demonstrated clear biological effects at 250mg/day — suggesting the gut-absorption concern may be overstated, especially given the Slc12a8 transporter's activity in the small intestine. Until direct comparative data exists, sublingual NMN is a reasonable experiment but not an evidence-based requirement. If cost is a factor, standard oral NMN from a quality-tested brand is a defensible choice.
Sinclair's personal stack famously includes NMN and resveratrol together. The theoretical rationale: NMN raises NAD+, which activates SIRT1 (a sirtuin). Resveratrol is an allosteric activator of SIRT1, theoretically amplifying sirtuin signaling beyond what NAD+ elevation alone achieves. Mouse studies from Sinclair's lab showed synergistic effects on metabolic parameters.
The human evidence for the combination is essentially absent — no RCT has tested NMN + resveratrol jointly vs. either alone. Resveratrol itself has a complicated track record in human trials (poor bioavailability, mixed results). Pterostilbene, a resveratrol analog with better oral bioavailability, is sometimes substituted. If you do stack, take resveratrol with a fat-containing meal to improve absorption — its bioavailability increases 2–4x with dietary fat.
Trimethylglycine (TMG, also called betaine) is a methyl donor. When NAD+ is synthesized and then consumed by enzymes like CD38 and PARPs, the metabolic byproduct is nicotinamide, which is methylated before excretion. At high NMN/NR doses, this methylation demand can theoretically deplete methyl groups — a concern for people with MTHFR variants or borderline B12/folate status.
Adding 500–1,000mg TMG daily alongside NMN or NR replenishes methyl donors preemptively. This is a precautionary stack rather than one with strong direct evidence, but it is low-risk, inexpensive (~$0.10–0.20/day), and commonly recommended by practitioners working with high-dose NAD+ precursor protocols. If you take more than 500mg/day NMN or NR, TMG is worth adding.
NMN: Start at 250mg in the morning, ideally with breakfast (or fasted — both appear to work). After 4–8 weeks, titrate to 500mg if no side effects and you want to match the upper range of the Yoshino trial. Some practitioners and self-experimenters use 1,000mg+, but human safety data above 1,200mg/day is limited. Morning dosing is preferred because NAD+ is involved in circadian rhythm regulation via SIRT1/NAMPT oscillations — evening doses may theoretically interfere with sleep in sensitive individuals.
NR: Start at 300mg in the morning. Most clinical trials used 500–1,000mg/day. The Martens trial (the most compelling) used 1,000mg/day, but cost at that dose is significant. 300–500mg is a practical daily maintenance dose with documented NAD+ uplift. Take with food if you experience GI discomfort.
Cycling: There is no strong evidence requiring cycling of NMN or NR. Some practitioners recommend 5 days on, 2 days off to prevent receptor downregulation, but the enzymatic pathways involved do not have known feedback loops that would make this necessary. Consistent daily dosing reflects how all published trials administered these compounds.
Side effects: Both are well-tolerated. The most commonly reported issues are mild GI discomfort (nausea, loose stools) at higher doses — typically resolving after 1–2 weeks or with dose reduction. Flushing, a classic niacin side effect, is rarely reported with either NMN or NR at standard doses.
You are interested in muscle metabolism and insulin sensitivity — the Yoshino trial's endpoint. You want to experiment with sublingual delivery. You are already following Sinclair's general longevity protocol and want consistency with the stack he advocates. You prefer the mechanistic argument of one fewer enzymatic step to NAD+. You are willing to pay a slight premium for what is currently the more actively researched molecule.
You prioritize the larger human RCT database — NR has more completed trials across more populations. You want a product with longer market history and more third-party safety data (Tru Niagen has FDA GRAS status and multiple safety reviews). You run warmer or live in a more humid climate and prefer a more shelf-stable supplement. You are cost-sensitive and want proven NAD+ uplift at moderate doses.
The most important variable is neither NMN nor NR — it is consistency. NAD+ declines steadily with age, and the precursor strategy only works if you actually take the supplement regularly. The best NAD+ precursor is whichever one you will take every morning for the next 10 years. If cost is what stops you, NR at 300mg/day from a reputable brand is a better choice than NMN at 500mg that sits in a drawer because it's expensive.
These are the brands with the cleanest third-party testing records and transparent manufacturing documentation as of mid-2026:
↗ Top NMN Supplements on Amazon ↗ Top NR Supplements on AmazonWhat to look for: Third-party COA (certificate of analysis) for purity and heavy metals. NMN purity should be ≥98%. For NR, look for brands using Niagen-licensed material (ChromaDex supply chain) — generic NR from unknown Chinese bulk suppliers has higher contamination risk. Both compounds should be stored below 25°C and away from humidity.
↗ Tru Niagen (ChromaDex NR) on Amazon ↗ Sublingual NMN on AmazonNMN has slightly more mechanistic rationale — one enzymatic step to NAD+, a potentially dedicated transporter, and an intriguing insulin-sensitivity signal in the Yoshino trial. NR has more human RCT data — a larger body of controlled trials, longer safety record, and better shelf stability.
Both raise NAD+. Both are safe at recommended doses. Both have credible science behind them. Take whichever you can afford to take consistently. Stack with TMG at doses above 500mg/day. Add resveratrol or pterostilbene if you want to extend the sirtuin hypothesis. And remember: no NAD+ precursor replaces exercise, sleep, and caloric quality — the interventions with the deepest longevity evidence base in humans.
If forced to choose: NMN 250–500mg/day for those optimizing for metabolic and muscle health; NR 300–500mg/day for those who prioritize conservative, well-validated human evidence. Neither choice is wrong.
Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229.
Martens CR, et al. (2020). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 11, 2813.
Dollerup OL, et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Nature Communications, 9, 3151.
Irie J, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160.
Grozio A, et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1, 47–57.
Elhassan YS, et al. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 28(7), 1717–1728.
Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. Journal of the International Society of Sports Nutrition, 18(1), 54.
Disclosure: LongevityLab participates in the Amazon Associates Program. Links marked with ↗ are affiliate links; we may earn a commission at no additional cost to you. This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement protocol.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.